The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid beneficiaries access to anti-obesity drugs such as the highly in-demand GLP-1 medications.

In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be covered by........

© The Hill